For the past fifteen years, Lymphoma & Myeloma has been the premier forum on the latest advances in lymphoma, myeloma, and other plasma cell neoplasms. Over forty internationally recognized leaders in molecular biology, pathology, immunology, translational and clinical research have been involved to provide expertise and guidance on recent developments in the basic science, translational medicine and clinical trials.
This Congress features an interdisciplinary approach, special lectures, debates and interactive techniques to explore the controversial, the upcoming, and the exciting in myeloma, Waldenstrom’s macroglobulinemia, chronic lymphocytic leukemia, lymphoma and Hodgkin’s disease.
In this abstract presentation, Dr. Steve Coutre discusses the use of 420 mg of single-agent ibrutinib to induce durable responses including complete responses (CRs) in patients with chronic lymphocytic leukemia (CLL) following long-term treatment.
A continuing education program is offered as a supplement to this webcast at the following location:
[ Ссылка ]
© 2015 Imedex, LLC.
